Red Light for EU Intellectual Property Rights Debate... Germany Opposes Patent Waiver

[Image source=EPA Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] On the 6th (local time), Germany expressed opposition to the temporary waiver of intellectual property rights (IPR) on COVID-19 vaccines supported by the United States.

A spokesperson for the German government stated in a press release that day, "We support the goal of supplying COVID-19 vaccines worldwide, but the constraints on vaccine production are not patent rights but production capacity and quality standards." They added, "Protection of intellectual property rights is the source of innovation," emphasizing, "It must remain so in the future."

Germany is home to BioNTech, which jointly developed the COVID-19 vaccine with Pfizer and is considered a domestic pharmaceutical company. Earlier that day, Ursula von der Leyen, President of the European Commission, said she was ready to discuss the IPR waiver, but difficulties are expected due to Germany's opposition.

France and Italy have stated their strong support for the IPR waiver. Spain agreed that the waiver is appropriate but noted that it does not guarantee vaccine supply to developing countries.

The EU plans to address the IPR discussion as an agenda item at meetings held over two days this week.

This content was produced with the assistance of AI translation services.